Regulatory Shift and Legal Action Boost Novo Nordisk Shares

Shares of the Danish pharmaceutical giant Novo Nordisk surged by more than 8% on Monday. This significant gain followed a dual development that alleviated competitive pressures in the lucrative U.S. weight-loss drug market.

A Competitor Exits the Arena

The positive momentum began when telemedicine provider Hims & Hers announced over the weekend that it would halt sales of its low-cost semaglutide product. Semaglutide is the active ingredient in Novo Nordisk’s blockbuster drug, Wegovy. The competitor’s offering, priced at a fraction of Wegovy’s cost, had been viewed by the market as a substantial threat to Novo’s pricing power in the multi-billion dollar sector. Its withdrawal was announced just days after its launch.

FDA Action Precipitates Change

This retreat came swiftly on the heels of a regulatory announcement. On Friday, February 6, the U.S. Food and Drug Administration (FDA) stated it would take action against compounded GLP-1 medications lacking official approval. The agency cited significant concerns regarding the quality, safety, and effectiveness of such products, which have been widely marketed as cheaper alternatives to approved drugs like Wegovy.

Hims & Hers pulled its product less than 48 hours after the FDA’s statement.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Novo Nordisk Launches Legal Offensive

Capitalizing on the shifting landscape, Novo Nordisk initiated a lawsuit against Hims & Hers on Monday. The company is seeking a permanent injunction against what it describes as “unapproved, nonauthentic, and untested copycat products.” This legal move follows a warning issued by Novo Nordisk on February 5, in which it accused the competitor of illegal mass production that endangered patients.

The combination of regulatory intervention and aggressive legal strategy has removed a key overhang that was weighing on investor sentiment toward Novo Nordisk’s stock.

Relief at a Critical Juncture

This favorable turn of events arrives at an opportune moment for the company. In the preceding week, Novo Nordisk shares had declined after management provided a cautious outlook for 2026, forecasting lower sales and profits. The primary reason given was “unprecedented pricing pressure” in the U.S. market, partly driven by the rise of compounding pharmacies. The FDA’s recent stance is now seen as mitigating a major component of that pressure.

Further support for the share price comes from an ongoing share repurchase program. Since February 4, Novo Nordisk has been authorized to buy back its own shares worth up to 15 billion Danish kroner over the next twelve months.